• Active Biotech AB, of Lund, Sweden, said the FDA cleared its investigational new drug application for a Phase II trial of prostate cancer drug TASQ (ABR-215050). The company plans to initiate a randomized, double-blind, placebo-controlled, 200-patient Phase II trial before the end of the year comparing TASQ to placebo. Data regarding the primary endpoint of disease progression are expected in 2009. In a previous Phase I trial, five of six patients had a decrease in prostate-specific antigen velocity of more than 50 percent compared to prior treatment, and three of those five patients exhibited a decrease in absolute PSA levels.

• Genmab A/S, of Copenhagen, Denmark, said partner F. Hoffmann-La Roche Ltd., of Basel, Switzerland, filed an investigational new drug application with the FDA for a Genmab antibody developed under the companies' 2001 collaboration. That filing triggers an undisclosed milestone payment from Roche. Under the agreement, Genmab creates human antibodies to a broad range of disease targets identified by Roche in return for milestone and royalty payments. In certain cases, Genmab might obtain product development rights. If all goals in the collaboration are reached, Genmab could receive as much as $100 million, plus royalties.

• Solvay Pharmaceuticals Inc., of Marietta, Ga., and Wyeth Pharmaceuticals, of Madison, N.J., received a "not approvable" letter from FDA for bifeprunox, an atypical antipsychotic under review for the acute treatment of schizophrenia and the maintenance of stable adults. Regulators want the firms to conduct a second efficacy trial to support a maintenance claim for the drug and provide more data, including information about a trial participant who died. The companies said they would continue to pursue approval of the product.

• Symyx Technologies Inc., of Santa Clara, Calif., is acquiring certain content and software products of MDL Information Systems from Elsevier Inc., of San Ramon, Calif., in a $123 million all-cash deal. The transaction is expected to close during the fourth quarter of 2007 and is subject to customary closing conditions and documentation, including clearance under applicable antitrust laws.

• TaiGen Biotechnology Inc., of Taipei, Taiwan, completed enrollment of a target 265 patents in its Phase II trial of Nemonoxacin (TG-873870) for adult community-acquired pneumonia. The double-blind study is designed to compare the drug's clinical and bacteriological success rates with those of levofloxacin. Data are expected in the fourth quarter. A Phase II trial also is planned in diabetic foot infections.

• Unigene Laboratories Inc., of Fairfield, N.J., acquired exclusive commercial rights from Queen Mary, University of London to a combination therapy targeting arthritis and inflammatory bowel disease and a novel peptide for cardiac reperfusion injury in heart attack and stroke. Unigene will gain rights to those inventions and to future developments in exchange for research funding of about $400,000 per year over the next three years, milestones based on clinical and commercial progress, and royalty payments representing a percentage of the firm's revenues.